Tetralogic Pharmaceuticals Corp (NASDAQ: TLOG) and Ohr Pharmaceuticals (NASDAQ:OHRP) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitabiliy, valuation, analyst recommendations, institutional ownership, earnings and risk.

Profitability

This table compares Tetralogic Pharmaceuticals Corp and Ohr Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tetralogic Pharmaceuticals Corp N/A N/A -73.81%
Ohr Pharmaceuticals N/A -117.89% -97.41%

Valuation and Earnings

This table compares Tetralogic Pharmaceuticals Corp and Ohr Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Tetralogic Pharmaceuticals Corp N/A N/A -$21.14 million ($1.76) -0.01
Ohr Pharmaceuticals N/A N/A -$27.89 million ($0.87) -0.69

Ohr Pharmaceuticals is trading at a lower price-to-earnings ratio than Tetralogic Pharmaceuticals Corp, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for Tetralogic Pharmaceuticals Corp and Ohr Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tetralogic Pharmaceuticals Corp 0 0 0 0 N/A
Ohr Pharmaceuticals 0 1 1 0 2.50

Ohr Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 1,566.67%. Given Ohr Pharmaceuticals’ higher probable upside, analysts plainly believe Ohr Pharmaceuticals is more favorable than Tetralogic Pharmaceuticals Corp.

Risk and Volatility

Tetralogic Pharmaceuticals Corp has a beta of 3, indicating that its share price is 200% more volatile than the S&P 500. Comparatively, Ohr Pharmaceuticals has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.

Institutional & Insider Ownership

2.7% of Tetralogic Pharmaceuticals Corp shares are owned by institutional investors. Comparatively, 8.3% of Ohr Pharmaceuticals shares are owned by institutional investors. 24.0% of Tetralogic Pharmaceuticals Corp shares are owned by company insiders. Comparatively, 17.4% of Ohr Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Tetralogic Pharmaceuticals Corp beats Ohr Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Tetralogic Pharmaceuticals Corp Company Profile

TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company’s histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.

Receive News & Ratings for Tetralogic Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetralogic Pharmaceuticals Corp and related companies with MarketBeat.com's FREE daily email newsletter.